2022 HEAL TRIAL Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns phase 3 double-blind, placebo-controlled, randomised controlled trial Objective: To assess the role of erythropoietin in conjunction with therapeutic hypothermia for neuroprotection in newborn infants with hypoxic-ischemic encephalopathy 501 Inclusion criteria: (1) Infants born at 236 weeks of gestation (2) 21 signs of perinatal depression […]